May 2021

Partnership will enable member orthopedic surgeons to identify potential drug-gene interactions to improve the patient experience and outcomes

RALEIGH, N.C. and LAKE FOREST, Calif. – May 24, 2021 – US Orthopedic Alliance (USOA) has selected 2bPrecise to provide its precision medicine platform to USOA’s network of more than 100 orthopedic surgeons. The 2bPrecise pharmacogenomics module initially will be rolled out to four member practices over the coming months, equipping USOA physicians with the ability to effectively identify potentially dangerous drug-gene interactions so that patients receive the safest, most effective care possible.

“We recognize that precision medicine represents a new standard in health care,” said Rick Salas, CEO of USOA. “We’re committed to delivering the services, technologies and infrastructure orthopedic surgeons need so they can factor patient genetic profiles into their diagnostic and treatment decisions. It truly is a win for both the patient and the provider.” Providers offering precision medicine programs often achieve a competitive advantage over other practices in their service areas, he adds.

The 2bPrecise platform will deliver workflow, data management and clinical decision functionality to USOA providers ordering pharmacogenomic tests (PGx). Specifically, doctors can leverage test results to make informed decisions about powerful pain medications, anticoagulants, antiemetics or other drugs they may prescribe for patients.

Salas continued, “Core to our mission is a commitment to providing orthopedists with specialty-specific services to manage and grow their practices while enhancing the patient experience. Physician members benefit from USOA’s business intelligence solutions, including revenue cycle management, contracting, risk management and value-based care services such as infrastructure, technology and data analytics.”

“We are delighted to work with USOA to bring precision medicine and other genomic insights into the orthopedic workflow”, said Assaf Halevy, CEO and co-founder of 2bPrecise. “USOA has demonstrated its strong leadership in this area and is committed to ensuring its physician members are successful while improving the health and lives of patients. Together, we will help accelerate a dimensional change in how safe orthopedic care is delivered.”

Please visit 2bPrecise Pharmacogenomics about learn more about the extensive value of PGx for more information.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.

About US Orthopedic Alliance

With deep expertise in health information technology and practice management, USOA is a management services organization that provides its network of physicians, group practices, ambulatory surgery centers, and specialty surgery hospitals with a full suite of services that enable growth and achieve operational efficiencies. For more information on USOA, please visit www.usorthopedicalliance.com.

Media Contacts:
Erica Navar
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Andrew Meehan
Meehan Business Advisers (for USOA)
(949) 285-0759
ameehan@meehanba.com

Leader in precision medicine solutions and multispecialty clinic customer to discuss the promise of genetic data at the point of care

RALIEGH, NC – May 17, 2021 – 2bPrecise, a leader in precision medicine solutions, will present on the value of pharmacogenomics (PGx) at the AMIA 2021 Clinical Informatics Conference. The company will be joined by longtime customer Murfreesboro Medical Clinic and SurgiCenter (MMC) for the virtual presentation, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care.” Together, 2bPrecise and MMC will explore ways health IT tools and PGx testing can improve medication safety, reduce adverse drug events and accelerate therapeutic value for patients.

“Pharmacogenomics, or how drugs interact with a patient’s genes, is incredibly valuable when it comes to determining the best medication for a patient,” said Dr. Joel Diamond, a practicing physician at Handelsman Family Practice in Pittsburgh, PA and chief medical officer at 2bPrecise. “Genetic profiles can eliminate trial-and-error prescribing by ensuring medications are safe and effective from the outset. As an organization on the forefront of precision medicine, we are thrilled to showcase at AMIA and share now MMC is leveraging our tools to better understand a patient’s genetic data and provide better care.”

Dr. Diamond and MMC Chief Medical Informatics Officer and President Dr. Nicholas Cote will draw from their successful implementations of PGx programs to explore the role IT plays in giving providers better insight into patients’ genetic data to help inform clinical decisions. The duo will also discuss the obstacles commonly encountered when initiating point-of-care precision medicine programs, lessons learned and best practices from implementing these programs within their own practices, and measurable outcomes the organizations have experienced.

“Leveraging genetic data to identify how patients will metabolize certain medications is a critical step in ensuring patients receive high-value care,” said Dr. Cote. “Powerful precision medicine solutions can give providers the necessary support to make care decisions with certainty. We look forward to presenting at AMIA and sharing our successes and real-world experiences with colleagues who might be considering similar programs.”

Drs. Diamond and Cote’s session, “Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care,” will take place virtually Thursday, May 20, 2021 from 1:00–2:00 PM ET.

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract
population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable
participation in research studies and more.

Media Contact:
Erica Navar
Account Executive
Aria Marketing (for 2bPrecise)
(909) 538-9541
enavar@ariamarketing.com

Prestigious Award Recognizes Outstanding Health and Medical Technology Products and Companies

RALEIGH, N.C., – May 11, 2021 – 2bPrecise, a leader in precision medicine solutions, today announced it has once again been selected as the winner of the “Best Overall Genomics Solution” award in the fifth annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

The cloud-based 2bPrecise platform delivers precision medicine insights to providers within their familiar workflow, across any electronic health record (EHR). The solution is built to interact with ever-evolving genetic/genomic knowledge sources and care guidelines, and is integrated as part of the complete compendium of patient information. This actionable data set helps drive better diagnoses and faster treatment.

Among its many functions, the platform optimizes manual, document-driven processes and deliver a consolidated view of patient genetic/genomic results within the clinical context. It works to simplify workflows and connect care teams across the enterprise – providers, genetic counselors, pathologists, pharmacists and more. Additionally, 2bPrecise delivers a consistent clinical experience across the organization when providers leverage genomics, no matter which EHR they use. Lastly, the platform enables leadership to govern clinical practice around genetic/genomic testing for greater efficiency and value.

“2bPrecise delivers a smart technology infrastructure that not only supports genomic data management today, but provides in-workflow access to valuable informational resources far into the future,” said James Johnson, managing director, MedTech Breakthrough. “2bPrecise delivers a breakthrough platform for scalable precision medicine and we are thrilled to extend our congratulations to the 2bPrecise team for its back-to-back ‘Best Overall Genomics Solution’ award win.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including robotics, clinical administration, telehealth, patient engagement, EHR, mHealth, medical devices, medical data and many more. This year’s program attracted more than 3,850 nominations from 17-plus countries throughout the world.

“Genomics is redefining the standard of care and we’re working with a wide variety of clients to help them build an informatics strategy to power transformative point-of-care solutions,” said Assaf Halevy, founder and CEO, 2bPrecise. “We’re honored to receive this 2021 MedTech Breakthrough Award again, and look forward to continued success and momentum as we drive innovation in precision medicine.”

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.